Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

BioUtah Statement on Launch of Altitude Lab, Largest Life Sciences Incubator in Utah


BioUtah President and CEO, Kelvyn Cullimore, issued the following statement following the announcement of the opening of Altitude Lab.

"This is truly a life sciences milestone in Utah. We applaud Recursion and the University of Utah for their leadership in founding Altitude Lab. With one of the fastest-growing life sciences sectors in the nation, Utah will benefit greatly from this unique incubator. It further expands our footprint in the region by supporting and accelerating our industry's innovators and early-stage companies, from device and diagnostics, to drug discovery and health information technology. In addition to its state-of-the-art 14,500 square foot lab facility, Altitude will offer resident companies workshops, mentoring, and non-dilutive funding resources that are so critical to success. This is really an effort to seed and nurture the next generation of life sciences companies in the state. BioUtah looks forward to supporting the lab and its residents as part of a larger strategy to establish Utah as a global hub for the life sciences."

About BioUtah

BioUtah is an independent 501(c)(6) trade association serving Utah's life sciences industry. Its member companies reflect a broad spectrum of the industry with strengths in medical device manufacturing and services, research and testing, biotechnology, biopharmaceuticals, and advanced diagnostics, amongst others; and are a key driver of Utah's economy.


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: